Teva Pharmaceutical stock (US88162G1031): Beats Q1 2026 earnings with CNS growth

Teva Pharmaceutical reported strong Q1 2026 results on April 29, beating EPS expectations at $0.53 versus estimates, driven by CNS portfolio sales up to $837 million. Shares traded at $36.26 on May 13.

Teva Pharmaceutical Industries Ltd. delivered robust first-quarter 2026 results on April 29, 2026, surpassing earnings expectations with EPS of $0.53 against a consensus of around $0.48-$0.65, according to Teva IR as of April 29, 2026. Central nervous system medicines like Ajovy, Uzedy, and Austedo generated $837 million in sales, reflecting very large year-on-year growth, as highlighted in recent conference presentations. The stock closed at $36.26 USD on NYSE on May 13, 2026, up 1.25%, per MarketBeat as of May 13, 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Teva Pharmaceutical Industries Ltd.
• Sector/industry: Pharmaceuticals
• Headquarters/country: Israel
• Core markets: US, Europe, global generics
• Key revenue drivers: Generics, CNS branded drugs
• Home exchange/listing venue: NYSE (TEVA)
• Trading currency: USD

Teva Pharmaceutical: core business model

Teva Pharmaceutical operates as a global leader in generic medicines and innovative branded drugs, with a portfolio spanning multiple therapeutic areas. The company focuses on affordability through generics while investing in high-growth branded products, particularly in neurology and respiratory categories. In Q1 2026, reported April 29, 2026, innovative portfolio growth drove overall performance, per Teva IR as of April 29, 2026.

Headquartered in Israel with major US exposure via NYSE listing, Teva serves patients in over 60 countries. Its business model balances high-volume generics with specialty pharmaceuticals, aiming for sustainable revenue through pipeline advancements like the recent Emalex acquisition boosting CNS capabilities.

Main revenue and product drivers for Teva Pharmaceutical

Generics remain a cornerstone, but branded CNS products led Q1 2026 growth with $837 million in sales for Ajovy, Uzedy, and Austedo, up significantly year-on-year, as noted in May 2026 conference updates from Simply Wall St as of May 2026. These drugs target migraines, schizophrenia, and Huntington's disease, respectively, tapping into expanding US markets.

Overall, Teva projects $18.1 billion in revenue by 2029 with 1.4% annual growth, per long-term guidance shared at the Bank of America Global Healthcare Conference in May 2026. US sales, a key driver, benefit from the company's dominant generics position and growing branded uptake.

Industry trends and competitive position

The pharmaceuticals sector sees rising demand for CNS treatments amid aging populations and mental health focus, areas where Teva's portfolio positions it competitively against peers like Pfizer and Eli Lilly. Q1 2026 results underscore Teva's execution in branded growth post-generic patent cliffs.

Why Teva Pharmaceutical matters for US investors

Listed on NYSE, Teva offers US investors exposure to global pharma with heavy US revenue reliance—over 40% from North America. Its generics leadership supports steady cash flows, while CNS innovations align with US healthcare spending trends on specialty drugs.

Conclusion

Teva Pharmaceutical's Q1 2026 earnings beat highlights momentum in its CNS portfolio, with strong sales growth and strategic presentations signaling confidence. Shares showed positive movement post-results, reflecting market attention on branded progress. Investors track upcoming quarters for sustained execution amid competitive pressures.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.